Where does Adimab, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Adimab, LLC ranks #7,228 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Adimab, LLC hold?

Adimab, LLC holds 45 US utility patents granted between 2016 and 2025, spanning 11 technology areas.

What is Adimab, LLC's Innovation Score?

Adimab, LLC has an Innovation Score of 42.3 out of 100 (top 31% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Adimab, LLC focus on?

Adimab, LLC's top technology area is C07K (Peptides) with 40 patents, ranking #239 of 3,615 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Adimab, LLC's patent grant rate increasing or decreasing?

Adimab, LLC's recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Adimab, LLC's patents?

Adimab, LLC's patents average 15.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Adimab, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Adimab, LLC

USPTO PatentsView assignee record - 45 granted patents across 11 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Adimab ranks #7,228 of 49,997 tracked US assignees by granted-patent volume, with 45 patents across 11 technology areas.

#7,228
of 49,997 US assignees by volume: Top 31%
by Innovation Score (42.3/100): 15.7
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7228 · US Corporation #7,228 · 45 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 45 grants
UPPER-Q #7,228/49,997
PHOTO-FINISH Alphonso
CPC-FOCUS C07K · 11 areas
INNOV-PAR 42.3/100
CLAIMS-RICH 15.7 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Alphonso Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Adimab’s 42.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.2 pts (31%) Velocity 7.9 pts (19%) Breadth 11.7 pts (28%) Claim depth 9.4 pts (22%)

Qualcomm Incorporated · highest

85
Adimab · this assignee

42
Equal1 Labs · near

42
Fujifilm Wako Pure… · near

42
Marchesini Group S P A · near

42
Swarovski-Optik & KG · near

42
3D Lighting… · lowest

7

What this shows Adimab's Innovation Score is 42.3/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Adimab?

Each dot is one of Adimab’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Adimab’s own 15.7 claims/patent is ABOVE the 14.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Adimab vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Adimab's grants concentrate

Adimab, LLC is a focused PatentsView assignee: 11 CPC subclasses with 88.9% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (13 grants) versus a trough of 2 in 2016. By volume, Adimab sits between Alphonso Inc. and Avegant Corp..

Adimab's three-year grant acceleration

Adimab, LLC shows 19 grants in 2022–2024 against only 16 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Alphonso

45
Altek Semiconduct…

45
APR Beauty Group

45
Aquastar Pool Pro…

45
Apollo Endosurgery

45
Atlas Global

45
Aurora Flight Sci…

45
Avegant

45
Adimab ◀

45

What this shows Adimab holds 45 patents at rank #7,234, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Adimab

By rank, the assignees closest to #7,234 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Adimab's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Adimab, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Adimab ranks #239 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Marchesini Group S.P.A. 42 Fujifilm Wako Pure Chemical Corporation 42 Swarovski-Optik AG & Co KG. 42 Equal1.Labs Inc. 42

Adimab's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Adimab, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	4.4%
2018	3	6.7%
2019	5	11.1%
2020	5	11.1%
2021	6	13.3%
2022	13	28.9%
2023	3	6.7%
2024	3	6.7%
2025partial year	5	11.1%

Which technologies does Adimab, LLC patent most?

C07K - Peptides 40

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 26

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 16

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 16

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 14

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 4

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 4

C12Y - Enzymes 3

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

B01D - Separation 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Adimab, LLC's patent record in context - here's where to go next.

Adimab, LLC's lead technology class is C07K (Peptides), 88.9% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #7,228 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Adimab, LLC against Alphonso Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.